News & Events

Montpellier, France, July 2024. SurgiMab is proud to announce the participation of Françoise Cailler, CEO & CSO, at the prestigious World Molecular Imaging Congress (WMIC2024) to be held in Montreal from September 9 to 14, 2024 https://wmis.org/wmic-2024-about/.
WMIC is a leading international conference dedicated to advances in molecular imaging, bringing together scientists, researchers and healthcare professionals from around the world. Françoise Cailler will present SurgiMab’s innovations in targeted imaging agents for fluorescence-guided surgery during the OSN (Optical Surgical Navigation) group session on September 10 https://wmis.org/wmic1/osn-2024/ . 
“It’s an honor to represent SurgiMab at WMIC2024 and to share our advances with the international scientific community,” says Françoise Cailler. “We are convinced that our innovations will transform the way surgeons approach cancer treatment. This group brings together researchers, clinicians and industry representatives, and offers us a perfect opportunity, within the WMIC2024 congress, to strengthen our collaborations and discover emerging trends from experts in the clinical and regulatory fields.”
To see the conference program, please follow this link.
Don’t hesitate to get in touch to schedule a face to face meeting with Françoise : fcailler(@)surgimab.com

Montpellier, France, October 2023. SurgiMab is very proud to be a Silver Sponsor for the international symposium on fluorescence-guided surgery that will take place at Hotel Arena in Amsterdam on Nov 2-3.
The symposium is organized by the Dutch Fluorescence Guided Surgery (DFGS) Group and International Society of Fluorescence Guided Surgery.The symposium is aimed at a broad clinical and scientific audience, including both experienced and inexperienced fluorescence users. Various examples of the use of indocyanine green (ICG) in daily practice will be discussed, as well as research on tumor-specific substances. Researchers and specialists will be present.  
The interdisciplinary nature of the symposium offers a unique opportunity to learn from insights gained in other subspecialties that you may not be familiar with. As a participant, you will also have the opportunity to get acquainted with fluorescence cameras from various manufacturers.
Don’t hesitate to get in touch with Françoise Cailler or Bérénice Framery during the meeting.
To see the conference program, please follow this link.
Don’t hesitate to get in touch to schedule a face to face meeting with Françoise : fcailler(@)surgimab.com

Montpellier, France, April 2023. SurgiMab will participate to the meeting “Optics in the Life Sciences” organized during the Optica Biophotonics Congress at Vancouver Hyatt Regency.
Françoise Cailler, President and Chief Scientific Officer of SurgiMab, is very pleased to have the opportunity to present the company’s latest clinical advances as an Invited Author during the “Clinical Translation of Optical Molecular Imaging and Image Guided Surgery” session on April 26 from 1:45 to 4:00 pm.
Don’t miss Françoise’s presentation at 3:30 PM Pacific Time in Room Regency F, and don’t hesitate to come and discuss the company’s progress and possible collaborations to advance the field of fluorescence-guided surgery together.
To see the conference program, please follow this link.
Don’t hesitate to get in touch to schedule a face to face meeting with Françoise : fcailler(@)surgimab.com

Montpellier, France, January  2022. SurgiMab will attend the Molecular-Guided Surgery meeting organized during SPIE Photonics West at the Moscone Center in San Francisco.
 
SurgiMAb is very happy to participate in person to this exciting conference that will gather together the best KOLs in the domain. After two years of remote interactions, this conference will be a great occasion to discover exciting novelties and discuss collaborations in person.
 
Don’t miss the talks by Hiroto Nishino 22 January 2022 • 4:15 PM  and Françoise Cailler, CEO and Scientific Director of SurgiMab 23 January 2022 • 3:45 PM Room 302 (Level 3 South of Moscone center).
Please see the program of the conference following this link.
Please feel free to contact Françoise Cailler to arrange a meeting at fcailler [at] surgimab [dot] com

SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery, organized by the Cleveland Clinic under the leadership of the ISFGS – Coral Gables, FL – Feb 15th and 16th, 2020.

Montpellier, France, February 2020. Françoise Cailler, CEO and Scientific Director of SurgiMab will attend this exciting congress, where world-renowned specialists will gather together during two days to discuss the latest advances in the field of Fluorescence-Guided Surgery. Sessions will cover basic concepts, the use of NIR technology for oncology, colorectal surgery and many more exciting and innovative fields.

Click here to get to the agenda of the conference.

Please feel free to contact Françoise Cailler to arrange a meeting at fcailler [at] surgimab [dot] com

SurgiMab is a sponsor of the BIOS conference entitled “Molecular-Guided Surgery: Molecules, Devices and Applications” that will be held in San Francisco on Feb 1st and 2nd, 2020 during the SPIE Photonics West meeting.

Montpellier, France, January 2020. SurgiMab is proud to be a sponsor of this internationally acknowledged conference, that gathers together the best specialists of Fluorescence Guided Surgery.

Don’t miss the presentations by André Pèlegrin: Antibodies, favorite tools for fluorescence-guided surgery, 02/02 at 10:30  and by  Ruben Meijer: Clinical translation of novel contrast agent for image guided surgery, 02/02 at 13:30.

Françoise Cailler, CEO and Scientific Director of the company, will also be present.

Click here to get to the conference program..

SGM-101 could provide a new approach for patients diagnosed with CRC, most of whom undergo surgery.

Montpellier, France, 17 octobre 2019 – SurgiMab today announces that the first US patient has been recruited in its pivotal Phase 3 clinical trial of SGM-101, in a patient with colorectal cancer (CRC).

The randomized Phase 3 trial, shall enroll 300 CRC patients in ten clinical centers in the US and in Europe.
The trial will assess the clinical benefit of using SGM-101 as the intraoperative imaging agent in Fluorescence-Guided Surgery procedures, to identify cancer lesions in real-time. Participating patients will receive 10mg of SGM-101 four days prior to the scheduled CRC surgery. Preliminary clinical data of the Phase 3 trial is expected in 2020.

Click here to get to the full Press Release

SGM-101 has the potential to be the first tumor-targeted fluorescent probe to be marketed for fluorescence-guided surgery (FGS).

Montpellier, France, 16 July 2019 – SurgiMab today announces that the first surgical procedure was carried out in a pivotal Phase 3 clinical trial of the Company’s lead product, SGM-101, in a patient with colorectal cancer (CRC).

The randomized Phase 3 trial, designed following discussions with the FDA and other regulators, aims to enroll 300 CRC patients in ten clinical centers in Europe and US, and will assess the clinical benefit of using FGS with SGM-101 as the intraoperative imaging agent to identify cancer lesions during the surgical procedure. Patients will be injected with 10mg of SGM-101 four days prior to the scheduled CRC surgical procedure. Preliminary clinical data of the Phase 3 trial is expected in 2020.

Press Release 16 July 2019

Dr. Alex Vahrmeijer’s team in Leiden publishes first results of the clinical use of SGM-101.

Montpellier, France 31st Jan 2018 – SurgiMab is very proud to announce that Dr. Alex Vahrmeijer’s team in Leiden University Medical Center (LUMC) published their clinical results in the Lancet Gastroenterology & Hepatology after using SGM-101 in patients undergoing surgery for colorectal cancer. The study demonstrates the safety of SGM-101 and shows it can influence clinical decision making during the surgical procedure for patients with colorectal cancer.

This publication illustrates an extremely important part of the work that has been done by SurgiMab to prepare the phase III clinical trial that is currently in preparation.

Click here to get to the abstract of the article.

Click here to get to Pubmed

SurgiMab sponsors the Molecular Guided Surgery conference that will take place during the SPIE Photonics West in San Francisco, 27-28 Jan 2018.

Montpellier, France Jan 2018 – SurgiMab is proud to be a sponsor of the Molecular Guided Surgery conference that will take place during the SPIE Photonics West Meeting on Saturday 27 and Sunday 28 January, 2018. The conference will gather together the best specialists of Molecules, Devices and Applications. Results will be presented for our SGM-101 compound in colorectal cancer surgery. Come and meet us there!

Click here for the detailed program of the conference.